"The Long Run"
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Last refreshed: ⓘ
Follow this podcast in the Metacast mobile app to refresh it and see new episodes.
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Mostafa Ronaghi, co-founder and executive board member of Cellanome, on developing technology to look at live cells and cellular interactions at scale.
Jonathan Bricker, professor in the cancer prevention program at Fred Hutchinson Cancer Center, on how to quit smoking with help from tech and biotech tools.
Chris Garcia, professor at Stanford University and co-founder of several biotech startups, on using protein engineering to advance new treatments for cancer and autoimmune diseases.
Ted Love, chairman of BIO, and Dr. Alan Anderson, executive director of Sickle Forward, on how to improve quality of life for sickle cell disease patients around the world.
Robert Ang, CEO of Cambridge, Mass.-based Vor Bio, on using CRISPR gene editing to alter bone marrow transplants and improve treatment of acute myeloid leukemia.
Rick Young, professor at MIT and co-founder of Syros Pharmaceuticals, CAMP4 Therapeutics, Omega Therapeutics, and Dewpoint Therapeutics, on studying gene expression for drug discovery.